leisure time -WSS

leisure time

author：comprehensive 2025-10-01 00:48:40 - browse：233

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Canadians with cystic fibrosis outlive Americans by a decade

WSS

Lupron, used to halt puberty in children, may cause lasting health problems

The FDA weighs the risks of candy

FDA has safety concerns on CRISPR

Maker of FluMist seeks to allow at

CDC recommends rationing of RSV shot due to shortages

Beware reading your test results before your doctor does

hotspot

leisure time

hotspot

Heart attack and stroke risk calculators need revising

Diversifying clinical trials isn't enough to close racial gaps: study

Medicare details structure of new drug price negotiation program

The wait for US passports is creating travel purgatory and snarling summer plans

Activists slam private health insurers over coverage restrictions

Physician subsidies by hospitals soar in wake of No Surprises Act

The cancer drug shortage isn’t new — and neither are the solutions

Drug cartel violence flares in western Mexico after vigilante leader's killing

The cancer drug shortage isn’t new — and neither are the solutions

Biden's order seeks to regulate AI risk without stifling innovation

knowledge

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout Newsletter: XBI biotech index, Akero Therapeutics

Being 'nonadherent' patient made me a more empathetic doctor

Physician subsidies by hospitals soar in wake of No Surprises Act

Cassava reveals details — and problems — with Alzheimer's study

Wikipedia

entertainment

focus

entertainment